My Blue Dots

DALLAS–(BUSINESS WIRE)–EoS Fitness, the national High Value. Low Price. (HVLP)® gym brand with more than 175 locations open or on the way, closed out Q4 strong.

RIYADH, Saudi Arabia–(BUSINESS WIRE)– #Biotechnology–In a landmark step towards advancing cancer care in the Middle East, BOSTON ONCOLOGY ARABIA and SPIMACO have signed a Memorandum of Understanding (MoU) to localize the production of advanced oral oncology treatments in the Kingdom. Announced at the CPHI Middle East conference, this partnership reflects a shared commitment to improving patient outcomes, fostering local expertise, and contributing to Saudi Arabia’s Vision 2030 goals for healthcare transforma

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Mirvie, a company bringing a personalized, predictive, and preventive approach to pregnancy complications, today announced the company was selected to present new research demonstrating the ability of the Mirvie RNA platform to predict the risk of severe fetal growth restriction in pregnancy. The abstract, “Prediction of severely small-for-gestational-age infants using a novel cell-free RNA model,” will be presented on Thursday, January 30, 2025 9:1

COPENHAGEN, Denmark & PALO ALTO, Calif.–(BUSINESS WIRE)–Glooko and Hedia launched their interoperable solution, combining connected care, remote patient monitoring, and digital therapeutics for diabetes.

LEIDEN, Netherlands–(BUSINESS WIRE)– #Adults–Azafaros B.V. today announced that its lead asset, nizubaglustat, has been granted orphan drug designation from regulatory authorities in both the United States and the European Union for the treatment of GM1 gangliosidosis. Additionally, the company’s Clinical Trial Application (CTA) for two global Phase 3 studies investigating the drug’s efficacy and safety in GM1/GM2 gangliosidoses and Niemann-Pick Type C (NPC) was approved by multiple European countries

SEATTLE–(BUSINESS WIRE)–Parse Biosciences, líder en soluciones de secuenciación unicelular accesibles y escalables, acaba de anunciar una importante ampliación de la funcionalidad de su kit Evercode™ WT Mega. Los investigadores ahora pueden analizar hasta 384 muestras y 1 millón de células en un solo ciclo, lo que abre nuevas posibilidades para estudios de alto rendimiento. Aunque las tecnologías de secuenciación unicelular no han dejado de avanzar, muchas de ellas siguen teniendo limitacione

NIJMEGEN, Pays-Bas–(BUSINESS WIRE)–Aiosyn, un innovateur pionnier dans le domaine des logiciels de pathologie basés sur l’IA pour le cancer et les maladies rénales, a annoncé que son algorithme de comptage des figures mitotiques a obtenu le marquage CE dans le cadre du règlement sur les dispositifs médicaux de diagnostic in vitro (IVDR) en vue d’une utilisation dans le domaine du diagnostic. Cette étape établit Aiosyn Mitosis Breast comme la première application certifiée IVDR pour le comptag

SEATTLE–(BUSINESS WIRE)–A Parse Biosciences, líder em soluções acessíveis e escalonáveis para sequenciamento de células individuais, anunciou hoje uma expansão significativa na funcionalidade do Evercode™ WT Mega Kit. Agora, os pesquisadores podem analisar até 384 amostras e 1 milhão de células em um único experimento, abrindo novas possibilidades para estudos de alto rendimento. Embora as tecnologias de células individuais tenham avançado constantemente, muitas ainda enfrentam limitações ao

NIJMEGEN, Niederlande–(BUSINESS WIRE)–Aiosyn, ein Pionier im Bereich KI-gestützter Pathologiesoftware für Krebs- und Nierenerkrankungen, hat bekannt gegeben, dass sein Algorithmus zur Zählung mitotischer Figuren die CE-Kennzeichnung gemäß der In-Vitro-Diagnostik-Verordnung (IVDR) für den Einsatz in der Diagnostik erhalten hat. Dieser Meilenstein etabliert Aiosyn Mitosis Breast als erste IVDR-zertifizierte Anwendung für die Mitosenzählung in der Brustkrebsdiagnostik und beschleunigt das Wachst

NIJMEGEN, Nederland–(BUSINESS WIRE)–Aiosyn, een baanbrekende vernieuwer in AI-aangedreven pathologiesoftware voor kanker en nieraandoeningen, heeft aangekondigd dat zijn algoritme voor het tellen van mitotische figuren CE-markering heeft gekregen onder de In Vitro Diagnostic Regulation (IVDR) voor gebruik in de diagnostiek. Deze mijlpaal bevestigt Aiosyn Mitosis Breast als de eerste IVDR-gecertificeerde toepassing voor mitosetelling in borstkankerdiagnose en versnelt de groei van het bedrijf